2024-10-05 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and markets a broad range of medicines.

**Performance Analysis:**

**1. Performance vs. S&P 500:**

* **Cumulative Return:** ABBV (155.82%) has outperformed the S&P 500 (VOO, 131.45%) by 24.37%. 
* **Relative Divergence:** The current relative divergence is 65.18%, indicating that ABBV's performance is in the top 65% of its historical performance range compared to the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** $196.82
* **5-day Moving Average:** $195.65
* **20-day Moving Average:** $194.54
* **60-day Moving Average:** $188.94

**3. Technical Indicators:**

* **RSI:** 58.48, indicating a neutral to slightly bullish trend.
* **PPO:** 0.02, suggesting a weak upward momentum.
* **Delta_Previous_Relative_Divergence:** -7.01, implying a recent short-term downward trend.
* **Expected Return:** 0.87%, representing the estimated maximum 5-year potential return relative to the S&P 500.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

The most recent earnings report (2024-07-25) showed that ABBV beat expectations with an EPS of 2.65, exceeding the expected 2.57. This demonstrates a continued positive trend in the company's earnings performance.

**5. News and Recent Issues:**

* **Recent Market Outlook:**  Analysts generally maintain a bullish outlook for ABBV, citing strong revenue growth driven by its key products, including Humira, Rinvoq, and Skyrizi. The company is also expected to benefit from the expansion of its biosimilar portfolio.
* **Analyst Opinions:** Most analysts rate ABBV as a "Buy" or "Hold," with a consensus price target slightly above the current trading price.
* **Performance Highlights:** ABBV has demonstrated a consistent track record of strong performance, driven by its innovative drug pipeline and strategic acquisitions. However, some concerns remain regarding the potential impact of competition from biosimilar products and the ongoing legal battles related to Humira.

**6. Overall Analysis:**

ABBV has shown strong performance with positive earnings trends, exceeding market expectations and outperforming the S&P 500. Technical indicators suggest a neutral to slightly bullish trend, although recent short-term movements indicate potential downward pressure. The company's long-term prospects remain positive, supported by its strong product portfolio and ongoing expansion strategies. However, investors should remain aware of the potential challenges posed by competition and ongoing legal disputes. 

**7. Conclusion:**

ABBV's strong performance, consistent earnings growth, and solid long-term prospects make it an attractive investment option for investors seeking exposure to the pharmaceutical industry. However, investors should conduct thorough research and consider the potential risks before making any investment decisions. 
